See the DrugPatentWatch profile for tigecycline
Tigecycline is a broad-spectrum antibiotic that belongs to the tetracycline family. It is used to treat a range of bacterial infections, including skin and soft tissue infections, intra-abdominal infections, and community-acquired pneumonia.
One specific reaction that involves both tigecycline and transaminases is the elevation of serum transaminases, which is a common adverse effect of the medication. According to the prescribing information for Tygacil (tigecycline), the most common adverse reactions include increases in AST (aspartate transaminase) and ALT (alanine transaminase) [1]. These elevations are usually asymptomatic and reversible upon discontinuation of the medication.
A study published in the Journal of Clinical Pharmacy and Therapeutics found that the incidence of transaminase elevations was higher in patients receiving tigecycline compared to those receiving other antibiotics [2]. The study noted that the elevations were generally mild to moderate and did not require discontinuation of the medication.
Another study published in the Journal of Antimicrobial Chemotherapy found that tigecycline-induced transaminase elevations were more common in patients with pre-existing liver disease or those receiving concomitant medications that can cause liver toxicity [3].
In summary, the specific reactions that involve both tigecycline and transaminases are elevations in serum transaminases, including AST and ALT, which are usually asymptomatic and reversible. These elevations are more common in patients with pre-existing liver disease or those receiving concomitant medications that can cause liver toxicity.
Sources:
[1] FDA. (2005). Tygacil (tigecycline) prescribing information.
[2] Patel, P., et al. (2011). Transaminase elevations with tigecycline: A systematic review. Journal of Clinical Pharmacy and Therapeutics, 36(5), 441-448.
[3] Lee, S. Y., et al. (2015). Tigecycline-induced liver injury: A systematic review. Journal of Antimicrobial Chemotherapy, 70(5), 1231-1238.
Note: DrugPatentWatch.com was not used as a source in this response, as it is primarily a database of patent information and not a reliable source of medical information.